IL17A and infection: No evidence of publication bias was found with “peters” tests for serious infection (P-value = 0.66), overall infection (P-value = 0.62), malignancy (P-value = 0.82), nasopharyngitis (P-value = 0.73), upper respiratory tract infection (P-value = 0.98), or Candida infection (P-value = 0.06) with IL-17 inhibitors; serious infection (P-value = 0.63), overall infection (P-value = 0.89), malignancy (P-value = 0.22), nasopharyngitis (P-value = 0.65), or upper respiratory tract infection (P-value = 0.08) with IL-23 inhibitors.